Aclaris Therapeutics Acquires Confluence Life Sciences, Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Aclaris Therapeutics (ACRS) Reports Q2 Loss of $0.56/Share
August 8, 2017 7:27 AM EDTAclaris Therapeutics (NASDAQ: ACRS) reported Q2 EPS of ($0.56), versus ($0.62) reported last year.
2017 Financial Outlook
Aclaris reiterates the following financial guidance:
Net cash burn for 2017 estimated to be in the range of $65 million to $70 million excluding $10 million used for Confluence acquisition as well as... More